A modern view of the development and approaches to the treatment of atopic dermatitis in children


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A review presents a modern view of the development and approaches to therapy for atopic dermatitis (AtD) in children based on litera- ture review and authors’ own research. The important role of atopy, mutations in the filaggrin gene, activation of Th2 lymphocytes, innate lymphoid cells (ILC), dendritic cells, mast cells, basophils, eosinophils, Langerhans cells, keratinocytes, Th1 cells, Treg, increased production of immunoglobulin E (IgE), mediators, chemokines and cytokines (IL-4, IL-5, IL-8, IL-9, IL-13, IL-17, IL-25, IL-31, interferon γ and tumor necrosis factor α), impaired skin barrier function in the pathogenesis of AtD is demonstrated. The clinical and immunologi- cal characteristics of IgE-mediated and non-IgE-mediated AtD are presented. The therapeutic efficacy of pathogenetic therapy for AtD using topical glucocorticosteroids, calcineurin inhibitors, emollients, antihistamines, anti-IgE therapy and allergen-specific immuno- therapy has been shown

Full Text

Restricted Access

About the authors

I. I Balabolkin

National Medical Research Center for Children's Health

Moscow, Russia

V. A Bulgakova

National Medical Research Center for Children's Health; Pirogov Russian National Research Medical University; Sechenov First Moscow State Medical University (Sechenov University)

Email: irvilbulgak@mail.ru
Doctor of Medical Sciences, Chief Researcher 2, build. 1, Lomonosovsky Prospect, Moscow 119991, Russian Federation

T. I Eliseeva

Privolzhsky Research Medical University

Nizhny Novgorod, Russia

References

  1. Балаболкин И.И., Булгакова В.А., Елисеева Т.И. Атопический дерматит у детей. М., 2018. 304 с
  2. Andersen Y.M.F, Egeberg A., Skov L., Thyssen J.P Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr Dermatol Rep. 2017;6(1): 35-41.
  3. Weidinger S., Novak N. Atopic dermatitis. Lancet. Lond Engl. 2016;387(10023):1109-22. doi: 10.1016/S0140-6736(15)00149-X.
  4. Silverberg J.H. Public health burder and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35:283-89. Doi: 10.1016/j. det.2017.02.002.
  5. Barbarot S, Auziere S., Gadkari A., et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284-93. doi: 10.1111/all.13401.
  6. Tsakok T, Woolf R., Smith C.H., et al. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2018;180(3):464-74.
  7. Malik K., Heitmiller K.D., Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017;35:317-26. Doi: 10.1016/j. det.2017.02.006.
  8. Tay Y.K. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol. 2002;146(1): 101-6.
  9. Bin L., Leung D.YM. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin lmmunol. 2016;12:52. doi: 10.1186/s13223-016-0158-5.
  10. Global atlas of allergy. Ed. by C.A. Akdis, I. Agache. European Academy of Allergy and Clinical Immunology. 2014. 388 p.
  11. van Smeden J., Janssens M., Kaye E.C.J., et al. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp Dermatol. 2014;23:45-52. Doi: 10.1111/ exd.12293.
  12. Dennin M., Lio P.A. Filaggrin and childhood eczema. Arch Dis Child. 2017;102(12):1101-1102. doi: 10.1136/archdischild-2017-313010.
  13. Osawa R., Akiyama M., Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1-9. doi: 10.2332/allergolin.10-RAI-0270.
  14. Balabolkin I.I., Larkova I.A., Bulgakova VA., et al. Mutations in the gene filaggrin in patients with atopic dermatitis as a risk factor for the severity of the disease. Allergy. 2016;71(Suppl. 102):300. doi: 10.1111/all.12974.
  15. Brown S.J. Molecular mechanisms in atopic eczema: insights gained from genetic studies. J Pathol. 2017;241(2):140-45. Doi: 10.1002/ path.4810.
  16. Janssens M., van Smeden J., Gooris G.S., et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res. 2012;53(12):2755-66. doi: 10.1194/jlr. P030338.
  17. van den Oord, RANM, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and metaanalysis. BMJ. 2009;339:b2433. Doi:10.1136/ bmj.b2433.
  18. Salimi M., Barlow J.L., Saunders S.P, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939-50.
  19. Kim B.S., Siracusa M.C., Saenz S.A., et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5:170.
  20. Kim B.S. Innate lymphoid cells in the skin. J Investig Dermatol. 2015;135:673-78. Doi: 10.1038/ jid.2014.401.
  21. Howell M.D., Kim B.E., et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Investig Dermatol. 2008;128(9):2248-58. Doi: 10.1038/ jid.2008.74.
  22. Furue M., Chiba T, Tsuji G., et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398-403. Doi: 10.1016/j. alit.2016.12.002.
  23. Penders J., Gerhold K., Stobberingh E.E., et al. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J Allergy Clin Immunol. 2013;132(3):601-7. doi: 10.1016/j.jaci.2013.05.043.
  24. Lee S.-Y., Lee E., Park Y.M., Hong S.-J., Hong S.J. Microbiome in the Gut-Skin Axis inAtopic Dermatitis. Allergy Asthma Immunol Res. 2018;10:354-62. doi: 10.4168/aair.2018.10.4.354.
  25. Moy A.P, Murali M., Kroshinsky D., et al. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis. JAMA. Dermatol. 2015;151:753-60. Doi: 10.1001/ jamadermatol.2015.2.
  26. Ezzat M.H., Hasan Z.E., Shaheen K.Y. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venerol. 2011;25(3):334-39. doi: 10.1111/j.1468-3083.2010.03794.x.
  27. Kim J.E., Kim J.S., Cho D.H., Park H.J. Molecular mechanisms of cutaneous inflammatory disorder: Atopic dermatitis. Int J Mol Sci. 2016;12:52. doi: 10.3390/ijms17081234.
  28. Thyssen J.P, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792-99. Doi: 10.1016/j. jaci.2014.06.014.
  29. Armeding D., Frank C., Rejsen D., et al. IgE and IgG in human B-cells cultures with staphylococcal super antigens: role of helper T-cell interaction, resistance to interferon gamma. Immunobiol. 1993;188:259-73.
  30. Балаболкин И.И., Садикова Т.Е. Клиникоиммунологические варианты атопического дерматита у детей и подростков и эффективность патогенетической терапии. Педиатрия. 2013;92(3):6-13.
  31. Valenta R., Seiberler S., Natter S., et al. Autoallergy: a pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol. 2000;105:432-37. Doi: 10.1067/ mai.2000.104783.
  32. Гервазиева В.Б., Самойликов П.В., Сверановская В.В. Современные аспекты иммунопатогенеза атопического дерматита. Российский аллергологический журнал. 2006;3:5-12.
  33. Hill D.J., Heine R.G., et al. The natural history of intolerance to soy and extensively hydrolyzed formula in infants with multiple food protein intolerance. J Pediatr. 1999; 135:118-21. doi: 10.1016/s0022-3476(99)70341-0.
  34. Феденко Е.С., Елисютина О.Г Федеральные клинические рекомендации. Атопический дерматит. Российский аллергологический журнал. 2017;3(14):35-45.
  35. Гребенюк В.Н., Балаболкин И.И. Прогресс в наружной кортикостероидной терапии атопического дерматита у детей. Педиатрия. 1998;5:88-91
  36. Капустина Е.Ю., Балаболкин И.И., Писарева И.В., Петричук С.В. Наружное лечение атопического дерматита кремом Элидел. Сборник материалов IV Российского конгресса «Современные технологии в педиатрии и детской хирургии». М., 2005. С. 26-7
  37. Svensson A, Chambers C., et al. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27(7):1395-406. doi: 10.1185/03007995.2011.582483.
  38. Healy E, Bentley A., Fidler C., et al. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice daily reactive treatment of exacerbations from a third party Br J Dermatol. 2011;164:387-95.
  39. Калюжин О.В. Персистирующее субклиническое воспаление в коже как фактор риска обострений атопического дерматита: от патофизиологии к лечению. Российский аллергологический журнал. 2017;4-5(14):108-18.
  40. Смирнова Г И. Наружная терапия атопического дерматита у детей - дифференцированный подход. Российский аллергологический журнал. 2012;(5):46-54
  41. Коростовцев Д.С., Пампура А.Н., Фассахов Р.С. и др. Клиническая эффективность и антимикробная активность пиритиона цинка при атопическом дерматите у детей. Педиатрическая фармакология. 2009;6(1):1-5
  42. Сидоренко О.А., Короткий Н.Г Эффективность иммуносупрессивной терапии атопического дерматита у детей. Российский журнал кожных и венерических заболеваний. 2008;4:65-7
  43. Кудрявцева А.В., Балаболкин И.И. Циклоспорин Автерапии тяжелых форм атопического дерматита. Вопросы практической педиатрии. 2009;5(4):18-21
  44. Sheinkopf L.E., Rafi A.W., Do L.T., et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530-37. doi: 10.2500/aap.2008.29.3160.
  45. Wang J., Sampson H. Safety of epicutaneous immunotherapy for food. Pediatr Allergy Immunol. 2018;29:341-49. doi: 10.1111/pai.12869.
  46. Niers L., Martin R., Rijkers G., et al. The effects of selected probiotic strains on the development of eczema (the Pand A study). Allergy. 2009;64:1349-58.
  47. Альбанова В.И., Пампура А.Н. Атопический дерматит. М., 2014. 125 с

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies